fig11
![Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy](https://image.oaes.cc/5feda047-3964-41e2-a778-a3e225051f4d/3827.fig.11.jpg)
Figure 11. Superior therapeutic activity of PLAD-MLP in the 4T1 tumor model (triple negative mouse breast carcinoma). BALB/c female mice were inoculated with 105 tumor cells subcutaneously in the right rear footpad. Treatment given intravenously on days 8 and 15. When Dox and MLP are co-encapsulated, the doses are shown as Dox/MLP respectively. N mice/group=5-8. Dose (1st → 2nd): PLD, 10 mg/kg → 8 mg/kg; PL-MLP, 35 mg/kg → 30 mg/kg; PLD+PL-MLP, 10 mg/kg + 16.8 mg/kg → 8 mg/kg + 13.5 mg/kg; PLAD-MLP, 10/16.8 mg/kg → 8/13.5 mg/kg. The median tumor size values for the PLAD-MLP were significantly different when compared to other groups (Wilcoxon matched-pairs signed rank test, P < 0.05)